- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00455975
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Bevacizumab is considered a targeted drug. Targeted drugs act on specific receptors on a cell. Bevacizumab blocks receptors that help cancer cells develop blood supplies so that the cancer can grow. These specific receptors are found in greater numbers in kidney cancer. In that regard bevacizumab will be tested in 2 doses that are higher than non-kidney cancer treatments with bevacizumab.
One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks. A total of 75 patients will be treated with this dose.
If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33901
- Florida Cancer Specialists
-
-
Georgia
-
Gainesville, Georgia, Stati Uniti, 30501
- Northeast Georgia Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40207
- Consultants in Blood Disorders and Cancer
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20817
- Center for Cancer and Blood Disorders
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68114
- Methodist Cancer Center
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Cancer Care of Western North Carolina
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45242
- Oncology Hematology Care
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Spartanburg Regional Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Chattanooga Oncology Hematology Associates
-
Collierville, Tennessee, Stati Uniti, 38017
- Family Cancer Center
-
Nashville, Tennessee, Stati Uniti, 37023
- Tennessee Oncology, PLLC
-
-
Virginia
-
Newport News, Virginia, Stati Uniti, 23601
- Peninsula Cancer Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically documented metastatic or unresectable locally recurrent clear cell renal carcinoma
- Previous kidney removal is required except if the primary tumor was smaller than 5 cm or there was extensive liver or bone metastasis
- Patients may have received a maximum of 1 prior systemic treatment of immunotherapy (Interferon, IL-2), chemotherapy, or combination chemo+immunotherapy for metastatic disease.
- No prior bevacizumab
- Measurable disease
- Adequate liver and kidney function
- Age 18 and older
Exclusion Criteria:
- Acute MI within the past 6 months
- Uncontrolled high blood pressure or history of hypertensive crisis
- Clinically significant cardiovascular disease
- Active brain cancer
- Meningeal metastasis
- Pregnant or lactating women
- Prior treatment for another cancer less than 5 years ago
- No diseases of the central nervous system (eg. uncontrolled seizures, strokes or TIAs
- No bleeding from the mouth, rectum or coughing up blood or history of other bleeding or clotting disorders
- No history of deep vein thrombosis less than 12 months ago or are currently requiring full dose anticoagulation
- No major surgical procedures, open biopsies or traumatic injury in past 28 days
- No patients with peg tubes or feeding tubes
- No patients with non healing wounds, ulcers or long bone fractures
- No history of abdominal fistulas, gastrointestinal perforation or intrabdominal abscess within 6 months
- No symptomatic peripheral vascular disease
Please note: there are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have. You can then decide if you wish to participate.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Weekly Avastin
Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
|
Bevacizumab
Altri nomi:
|
|
Sperimentale: Bi-weekly Avastin
Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
|
Bevacizumab
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free Survival
Lasso di tempo: 18 months (expected)
|
Progression-free survival is measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death on study.
Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
|
18 months (expected)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: 18 months
|
Measured from date of study entry to date of death due to any cause.
|
18 months
|
|
Objective Response Rate
Lasso di tempo: 18 months
|
The number of patients with observed complete response [CR] or partial response [PR].
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR
|
18 months
|
|
Overall Tolerability and Toxicity of High-dose Bevacizumab
Lasso di tempo: 18 months
|
Number of patients treated with high-dose bevacizumab experiencing Grade 3/4, treatment-related toxicities
|
18 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Cattedra di studio: John D. Hainsworth, M.D., SCRI Development Innovations, LLC
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie urologiche
- Neoplasie urogenitali
- Neoplasie per sede
- Malattie renali
- Malattie urologiche
- Adenocarcinoma
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie renali
- Carcinoma, cellule renali
- Carcinoma
- Effetti fisiologici delle droghe
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Bevacizumab
Altri numeri di identificazione dello studio
- SCRI GU 43
- AVF 3913s
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .